Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.

@article{Sechaud2008AbsenceOA,
  title={Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.},
  author={Romain Sechaud and Anna S. Robeva and Rossella Belleli and S{\'e}bastien Balez},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2008},
  volume={46 10},
  pages={
          519-26
        }
}
  • R. SechaudA. Robeva S. Balez
  • Published 1 October 2008
  • Biology, Medicine
  • International journal of clinical pharmacology and therapeutics
UNLABELLED Deferasirox (Exjade, ICL670) is a potent iron chelator, recently approved as first-line therapy for the treatment of blood-transfusion-related iron overload. Iron deposition in the heart may lead to cardiac dysfunction in patients with iron overload. Thus, the combination of cardiac glycosides and deferasirox is likely to be used in clinical practice. OBJECTIVE This study was designed to investigate the effect of deferasirox on steady-state pharmacokinetics of digoxin. As digoxin… 

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

Linagliptin did not alter the pharmacokinetics of digoxin in this study, indicating that linagli leptin does not inhibit P-glycoprotein or other transporters relevant for digoxin pharmacokinetic parameters, and suggests that linAGliptin and digoxin can be co-administered without dose adjustment.

Clinical Pharmacology of Deferasirox

  • C. Tanaka
  • Medicine, Biology
    Clinical Pharmacokinetics
  • 2014
A substantial body of clinical and pharmacokinetic data are available for deferasirox to guide its optimal use in multiple patient populations and clinical circumstances.

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

The aim of this review is to better identify those non-thalassemic patients who can benefit from ICT and give practical tips for management of this therapeutic strategy.

Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo

The aim was to calibrate the experimental system to allow better in vivo predictions of MDR1 interactions from in vitro to in vivo, and identified an [I2]/IC50(ER) of 6.5 as the best predictor of a potential interaction with digoxin in patients.